Statera Biopharma (STAB) Competitors $0.0001 0.00 (0.00%) As of 03/28/2025 09:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock STAB vs. SCPS, VAXX, NAVB, EVLO, CMRA, GNCAQ, GNCA, ARDS, CALA, and EFTRShould you be buying Statera Biopharma stock or one of its competitors? The main competitors of Statera Biopharma include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Calithera Biosciences (CALA), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Statera Biopharma vs. Scopus BioPharma Vaxxinity Navidea Biopharmaceuticals Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Calithera Biosciences eFFECTOR Therapeutics Scopus BioPharma (NASDAQ:SCPS) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking. Which has more risk and volatility, SCPS or STAB? Scopus BioPharma has a beta of -0.22, indicating that its share price is 122% less volatile than the S&P 500. Comparatively, Statera Biopharma has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Does the media favor SCPS or STAB? In the previous week, Scopus BioPharma had 1 more articles in the media than Statera Biopharma. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Statera Biopharma. Scopus BioPharma's average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Statera Biopharma Neutral Does the MarketBeat Community favor SCPS or STAB? Scopus BioPharma received 2 more outperform votes than Statera Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo VotesStatera BiopharmaN/AN/A Is SCPS or STAB more profitable? Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Statera Biopharma N/A N/A N/A Which has better earnings & valuation, SCPS or STAB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/AStatera BiopharmaN/AN/AN/AN/AN/A SummaryScopus BioPharma beats Statera Biopharma on 2 of the 3 factors compared between the two stocks. Remove Ads Get Statera Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STAB vs. The Competition Export to ExcelMetricStatera BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5,000.00$6.90B$5.63B$7.84BDividend YieldN/A2.74%4.57%4.01%P/E RatioN/A7.1723.3318.67Price / SalesN/A218.10387.5490.66Price / CashN/A65.6738.1634.64Price / BookN/A6.396.894.23Net IncomeN/A$142.12M$3.20B$247.15M7 Day PerformanceN/A-5.06%-2.98%-2.18%1 Month PerformanceN/A-7.49%1.63%-5.68%1 Year PerformanceN/A-10.91%9.44%-0.74% Statera Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5,000.00N/A0.0020SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009VAXXVaxxinityN/A$0.00flatN/A-99.3%$13,000.00N/A0.0090Gap DownNAVBNavidea BiopharmaceuticalsN/A$0.00-50.0%N/A-98.9%$10,000.00$8,126.000.0010Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9,000.00N/A0.00120Upcoming EarningsCMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070Gap UpGNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastNews CoverageARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.9%$5,000.00$3.09M0.0030CALACalithera BiosciencesN/A$0.00flatN/A-97.6%$3,000.00N/A0.0060EFTReFFECTOR TherapeuticsN/A$0.00flat$24.00+3,999,900.0%-100.0%$3,000.00$3.55M0.0010Upcoming Earnings Remove Ads Related Companies and Tools Related Companies Scopus BioPharma Competitors Vaxxinity Competitors Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Calithera Biosciences Competitors eFFECTOR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STAB) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy STAB Stock Free STAB Stock Alerts